CRSP Stock Falls -18% In 6-Day Spree On CEO Share Sale And Analyst Downgrade
CRISPR Therapeutics (CRSP) – a gene editing company developing therapies for genetic diseases – hit a 6-day losing streak, with cumulative losses over this period amounting to -18%. The company’s market cap has crashed by about $991 Mil over the last 6 days and currently stands at $4.6 Bil.
The stock has YTD (year-to-date) return of 4.7% compared to 1.4% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Slide?
[1] CEO Insider Selling
- CEO sold 90,000 shares between Jan 20 and Jan 22
- Stock fell 5.8% after the sales were reported
- Impact: Significant price decline, Increased investor concern
[2] Analyst Price Target Reduction
- Citizens analyst lowered price target to $80 from $86
- Weiss Ratings reiterated a “sell” rating on January 21st
- Impact: Negative sentiment reinforced, Contributed to downward momentum
Opportunity or Trap?
Below is our take on valuation.
There are a few things to fear in CRSP stock given its overall Weak operating performance and financial condition. But keeping in mind its Very High valuation, we think that the stock is Very Unattractive (For details, see Buy or Sell CRSP).
But here is the real interesting point.
You are reading about this -18% move after it happened. The market has already priced in the news. To avoid the next loser before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has a risk model designed to reduce exposure to losers.
Returns vs S&P 500
The following table summarizes the return for CRSP stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | CRSP | S&P 500 |
|---|---|---|
| 1D | -6.4% | -0.4% |
| 6D (Current Streak) | -17.8% | 0.4% |
| 1M (21D) | -6.1% | 0.6% |
| 3M (63D) | -20.1% | 0.7% |
| YTD 2026 | -4.7% | 1.4% |
| 2025 | 33.2% | 16.4% |
| 2024 | -37.1% | 23.3% |
| 2023 | 54.0% | 24.2% |
Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: CRSP Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 48 S&P constituents with 3 days or more of consecutive gains and 71 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 28 | 25 |
| 4D | 13 | 21 |
| 5D | 5 | 11 |
| 6D | 2 | 8 |
| 7D or more | 0 | 6 |
| Total >=3 D | 48 | 71 |
Key Financials for CRISPR Therapeutics (CRSP)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $370.0 Mil | $35.0 Mil |
| Operating Income | $-222.5 Mil | $-466.6 Mil |
| Net Income | $-153.6 Mil | $-366.3 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-229.3 Mil | $-132.1 Mil |
| Net Income | $-208.5 Mil | $-106.4 Mil |
The losing streak CRSP stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.